Imagion Biosystems Ltd (ASX: IBX) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Imagion Biosystems Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $2.45 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 32.65 million
Earnings per share -0.416
Dividend per share N/A
Year To Date Return -79.15%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Imagion Biosystems Ltd (ASX: IBX)
    Latest News

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Healthcare Shares

    The Imagion Biosystems (ASX:IBX) share price just exploded by 60%. Here's why

    What a turnaround! Imagion shares are skyrocketing after hitting a 52-week low yesterday.

    Read more »

    young female doctor with digital tablet looking confused.
    Share Gainers

    The Imagion Biosystems (ASX:IBX) share price leapt 40% in 2 days this week. What's happening?

    The biotech company has responded to a query from the ASX. Here are the details

    Read more »

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Healthcare Shares

    Imagion Biosystems (ASX:IBX) share price soars 13% on quarterly update

    Here's what is driving the Imagion share price higher today.

    Read more »

    rising medical asx share price represented by excited doctors dancing in ward
    Share Gainers

    Imagion (ASX:IBX) share price zips 38% higher. Here's why

    The Imagion Biosystems Ltd share price is up 38% today following an update on its MagSense HER2 breast cancer study.…

    Read more »

    ASX bank profit upgrade Red rocket and arrow boosting up a share price chart
    Healthcare Shares

    Imagion (ASX:IBX) share price up 1,166% in a year pursuing 'radiation-free' cancer tech

    The Imagion Biosystems Ltd share price has rocketed 1,166% over the past 12 months due to a series of promising…

    Read more »

    IBX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Imagion Biosystems Ltd

    Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    20 Dec 2023 Isaac Bright Issued 187,500 $64,687
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Brett Anthony Mitchell Non-Executive Director Jun 2024
    Mr Mitchell is a corporate finance executive with more than 15 years of experience in ASX listed companies leading transactions in the biopharmaceutical, mining, energy and tech industries. He has been involved in the founding, financing, and management of both private and publicly-listed companies, including recently as a director of ASX listed lithium developer Delta Lithium Ltd (DLI), the dual ASX-LSE listed medical cannabis company Argent Biopharma Ltd (RGT), and is currently Executive Chairman of ASX listed Javelin Minerals Ltd (ASX:JAV) and Non-Executive Chairman of Uvre Limited (ASX :UVA).
    Mr Michael (Mike) John Harsh Non-Executive Director Feb 2017
    Mr Harsh is a co-founder and Chief Product Officer of Terapede Systems, a digital X-ray startup that focuses on developing an ultra-high resolution medical flat panel X-ray detector. Prior to co-founding Terapede Systems in 2015, Mr. Harsh had a 36-year long career with General Electric, including serving as Global Technology Leader Imaging Technologies at the GE Global Research Center and culminating with him serving as Vice President and Chief Technology of GE Healthcare. He had previously served as a director for FloDesign Sonics until its acquisition by MilliporeSigma, a division of the Merck Group. He is member of Risk Committee.
    Mr Mark Gerald Van Asten Non-Executive Director Dec 2016
    Mr Asten has over 30 years of experience in the medical diagnostics and life sciences industry. Much of this time has been in international business development, strategic planning, and introduction of new technology. Through Diagnostic Technology, a company he founded, he has been responsible for the development and introduction of several innovative technology platforms and technologies into mainstream healthcare use, including HPV DNA testing for cervical cancer screening and the molecular monitoring for both viral infections and cancer treatments. He is also a member of Risk Committee.
    Mr David Gerald Ludvigson Non-Executive Director Mar 2017
    Mr Ludvigson is currently a director (was formerly President and CEO) af Nanomix, a point-of-care diagnostic medical device company. David is a financial and operating executive with over 35 years of international experience in life sciences and technology companies including Biogen (formerly IDEC Pharmaceuticals), Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems. His experience over 15 years in the diagnostics arena has led numerous new product efforts from concept to market launch. David has conducted many strategic transactions including multiple acquisitions, corporate partnerships, technology and intellectual property licensing agreements, and OEM relationships and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. He is also a member of Risk and Disclosure Committee.
    Mr Robert Romeo Proulx Executive DirectorExecutive Chairman Dec 2016
    Mr Proulx has been CEO and President of Imagion Biosystems since February 2015. Previous employment experience includes President / General Manager for Silicon Biosystems and a career in marketing and sales management with more than 25 years experience in the computer, life science and medical diagnostics industries. Some of Robert's other relevant experience includes Vice President Marketing and Sales for Nanogen Inc.; Senior Vice President of Marketing and Business Development at Gene Logic; and General Manager, Life Sciences at IGEN International Inc.
    Ms Melanie Jaye Leydin Company Secretary May 2024
    Yalia Jayalakshmi Chief Development Officer
    Melanie Jaye Leydin Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 56,178,508 5.01%
    Citicorp Nominees Pty Limited 27,944,616 2.49%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 11,369,662 1.01%
    Mr Haojie Li 11,000,000 0.98%
    The Board Of Regents Of The University Of Texas System 10,529,053 0.94%
    BNP Paribas Noms Pty Ltd <Drp> 10,310,929 0.92%
    Mr Yusuf Kucukbas <Yasep A/C> 9,999,990 0.89%
    E & W Nominee Pty Ltd <Liang Family Super Fund A/C> 9,609,498 0.86%
    Mr Anestis Lazaridis 8,830,703 0.79%
    Wh & Pr Pty Ltd <Robhoo Unit A/C> 8,000,000 0.71%
    G & D Finn Pty Ltd 7,000,000 0.62%
    Mr Feeras Najjar <Najjar Family A/C> 6,750,000 0.60%
    Mr Gj Howlett & Mrs Mw Howlett <Gh Super Fund A/C> 6,740,000 0.60%
    Mr Robert Proulx 6,163,250 0.55%
    Mr Yoanto Wakimin 5,594,681 0.50%
    HSBC Custody Nominees (Australia) Limited i 5,401,069 0.48%
    HSBC Custody Nominees (Australia) Limited A/C 2 5,161,262 0.46%
    Azzams Trading Pty Ltd 5,000,000 0.45%
    Bairdos Pty Ltd 5,000,000 0.45%
    Dr Russell Kay Hancock 4,000,000 0.36%